Search

Your search keyword '"Benedict CA"' showing total 98 results

Search Constraints

Start Over You searched for: Author "Benedict CA" Remove constraint Author: "Benedict CA"
98 results on '"Benedict CA"'

Search Results

1. Phenotypic heterogeneity follows a growth-viability tradeoff in response to amino acid identity

2. Novel functional insights into ischemic stroke biology provided by the first genome-wide association study of stroke in indigenous Africans

3. Continuous activity of Foxo1 is required to prevent anergy and maintain the memory state of CD8+ T cells

4. Determinants of First‐Ever Stroke Severity in West Africans: Evidence From the SIREN Study

5. Neutrophils Recruited by IL-22 in Peripheral Tissues Function as TRAIL-Dependent Antiviral Effectors against MCMV

6. Factors associated with hypertension among stroke‐free indigenous Africans: Findings from the SIREN study

7. Biological sample donation and informed consent for neurobiobanking: Evidence from a community survey in Ghana and Nigeria.

8. Chemical Profiling of Limonium vulgare Mill. Using UHPLC-DAD-ESI/MS2 and GC-MS Analysis

9. Prevalence and correlates of multiple non-communicable disease risk factors among adults in Zambia: results of the first national STEPS survey in 2017

10. Unraveling the Ethical, Legal, and Social Implications of Neurobiobanking and Stroke Genomic Research in Africa: A Study Protocol of the African Neurobiobank for Precision Stroke Medicine ELSI Project

11. The Occurrence of Richter’s Syndrome during Treatment with Obinutuzumab and Chlorambucil

12. Dominant modifiable risk factors for stroke in Ghana and Nigeria (SIREN): a case-control study

13. Knowledge, attitudes and practices related to stroke in Ghana and Nigeria: A SIREN call to action.

14. CMV immune evasion and manipulation of the immune system with aging

15. PD-1 and CD73 on naive CD4 + T cells synergistically limit responses to self.

16. A noncanonical glycoprotein H complex enhances cytomegalovirus entry.

17. Overexpression of native carbonic anhydrases increases carbon conversion efficiency in the methanotrophic biocatalyst Methylococcus capsulatus Bath.

18. Late-rising CD4 T cells resolve mouse cytomegalovirus persistent replication in the salivary gland.

19. Histamine-releasing factor in severe asthma and rhinovirus-associated asthma exacerbation.

20. Divergent metabolic programmes control two populations of MAIT cells that protect the lung.

22. Profiling Human Cytomegalovirus-Specific T Cell Responses Reveals Novel Immunogenic Open Reading Frames.

23. Pathogenic Autoimmunity in Atherosclerosis Evolves From Initially Protective Apolipoprotein B 100 -Reactive CD4 + T-Regulatory Cells.

24. Cellular sensing of extracellular purine nucleosides triggers an innate IFN-β response.

25. Cytomegalovirus Evades TRAIL-Mediated Innate Lymphoid Cell 1 Defenses.

26. Structure of human cytomegalovirus UL144, an HVEM orthologue, bound to the B and T cell lymphocyte attenuator.

27. Restriction of Human Cytomegalovirus Infection by Galectin-9.

28. Interleukin-17D and Nrf2 mediate initial innate immune cell recruitment and restrict MCMV infection.

29. IL-27 regulates the number, function and cytotoxic program of antiviral CD4 T cells and promotes cytomegalovirus persistence.

30. Cytomegalovirus: Shape-Shifting the Immune System.

31. Continuous activity of Foxo1 is required to prevent anergy and maintain the memory state of CD8 + T cells.

32. Crystal structure of murine 4-1BB and its interaction with 4-1BBL support a role for galectin-9 in 4-1BB signaling.

33. A noncanonical function of cGAMP in inflammasome priming and activation.

35. CMV immune evasion and manipulation of the immune system with aging.

36. N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death.

37. cGAS-STING Signaling Regulates Initial Innate Control of Cytomegalovirus Infection.

38. Cytomegalovirus-Specific CD4 T Cells Are Cytolytic and Mediate Vaccine Protection.

39. Cardif (MAVS) Regulates the Maturation of NK Cells.

40. Inhibition of the TRAIL death receptor by CMV reveals its importance in NK cell-mediated antiviral defense.

41. Distinct requirements for activation of NKT and NK cells during viral infection.

42. Neutrophils recruited by IL-22 in peripheral tissues function as TRAIL-dependent antiviral effectors against MCMV.

43. A CMV vaccine: TREATing despite the TRICKs.

44. CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells.

45. Lymphoid-tissue stromal cells coordinate innate defense to cytomegalovirus.

46. CD27-CD70 costimulation controls T cell immunity during acute and persistent cytomegalovirus infection.

47. The myeloid transcription factor GATA-2 regulates the viral UL144 gene during human cytomegalovirus latency in an isolate-specific manner.

48. Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses.

49. Structure of human cytomegalovirus UL141 binding to TRAIL-R2 reveals novel, non-canonical death receptor interactions.

50. Clinical targeting of the TNF and TNFR superfamilies.

Catalog

Books, media, physical & digital resources